26-03-2018
ericsphotography / iStockphoto.com
UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Indivior, generics, Suboxone, Alvogen, patent infringement, non-infringement, opioid addiction, ANDA,
US judge invalidates Pernix patents in Alvogen clash
28-08-2018
Indivior obtains court order to block generic Suboxone
18-06-2018
Indivior settles addiction drug dispute with Par
16-05-2018
Indivior settles generic dispute with Mylan
28-09-2017
Indivior to appeal court verdict over Suboxone Film patents
04-09-2017
